

CHAMPIONS BIOTECHNOLOGY, INC.  
Form 8-K  
July 30, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)  
July 30, 2008

**CHAMPIONS BIOTECHNOLOGY, INC.**  
(Exact name of registrant as specified in its charter)

Delaware (State of other jurisdiction of incorporation)	0-17263 (Commission File Number)	52-1401755 (IRS Employer Identification No.)
---------------------------------------------------------------	----------------------------------------	----------------------------------------------------

1400 North 14 <sup>th</sup> Street Arlington, VA (Address of principal executive offices)	22209 (Zip Code)
-------------------------------------------------------------------------------------------------	---------------------

Registrant's telephone number, including area code: (410) 630-1313

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

**Item 2.02 Results of Operations and Financial Condition.**

On July 30, 2008, Champions Biotechnology, Inc. ("Company") issued a press release announcing its financial results for the fiscal year ended April 30, 2008. The text of the press release is furnished herewith as Exhibit 99.1.

Exhibit 99.1 is furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such exhibit be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press release July 30, 2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 30, 2008

CHAMPIONS BIOTECHNOLOGY, INC.

By:

/s/ Douglas D. Burkett  
Douglas D. Burkett  
President